The British pharmaceutical group GlaxoSmithKline (GSK) saw its net profit group share decline 6% in the third quarter despite an increase in turnover due in particular to high taxes, but raised its forecasts.
Its net profit stood at 1.17 billion pounds on sales up 5% year on year to 9.08 billion pounds, according to a statement Wednesday.
Read alsoAfter GSK, the Elliott fund is interested in the British energy supplier SSE
Emma Walmsley, CEO of the group, particularly welcomed "
double-digit growth in pharmaceuticals and vaccines, the rise of the consumer health branch and the maintenance of discipline on costs
".
These results have enabled us "
to improve our annual forecasts and (...) strengthen our confidence in the prospects for a radical change in growth and performance in 2022 and beyond,
" she said.
No vaccine against covid-19
GSK now expects adjusted earnings per share in 2021 to drop between 2% to 4% excluding the contribution of its solutions against Covid-19 which "
represents an improvement over the previous estimate of July 2021
" .
Shortly before 11:30 a.m. GMT, GSK shares rose 2.37% to 1,468.20 pence on the London Stock Exchange.
The good reception of these figures on the stock market plays in favor of Mrs. Walmsley, contested by two investment funds which ask for his departure, criticize his balance sheet and in particular the mediocre performance of the action since his arrival.
Read alsoA new investment fund calls for the replacement of the head of GSK
GSK is also criticized for not having yet brought a vaccine against Covid-19 to the market.
The group announced at the end of August the launch with the South Korean SK Bioscience of advanced phase 3 trials for a candidate vaccine against Covid-19, very late in particular on the British Astrazeneca.
